Potent and selective mTOR inhibitor (IC50
= 2.1 nM). Displays 800-fold cellular selectivity for mTOR over PI3K (cellular EC50
values are 0.25 and 200 nM for mTOR and PI3K respectively). Orally available.
Soluble to 20 mM in DMSO
Store at +4°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from Whitehead Institute for Biomedical Research.
Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Liu et al.
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.
Simioni et al.
The citations listed below are publications that use Tocris products. Selected citations for Torin 2 include:
Showing Results 1 - 9 of 9